Cell And Gene Therapies Will Expand Secular Bioproduction
AN
AnalystHighTarget
Not Invested
Consensus Narrative from 20 Analysts
Published
11 Jun 25
Updated
23 Jul 25
AnalystHighTarget's Fair Value
€310.00
42.7% undervalued intrinsic discount23 Jul
€177.50
1Y
-28.1%7D
-7.3%